Entities / Technology
mash.
fast genome and metagenome distance estimation using MinHash
- Reports this week
- 0
- Active events
- 0
- Connections
- 36
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Wave Life Sciences is developing WVE-007, an investigational GalNAc-siRNA product, for MASH indications.Some support2 reports
-
INVENTIVA, a company focusing on MASH therapies, held leadership conferences in New York City and Brussels.Some support8 reports
-
Altimmune successfully launched its global Phase 3 trial in MASH and received Breakthrough Therapy Designation from the FDA.Some support2 reports
-
Hélène Mercier develops treatments for MASH and obtains an AMP from INSEAD.Some support1 report
-
Tangram Therapeutics is developing investigational treatments aimed at addressing the condition MASH (metabolic dysfunction-associated steatohepatitis).Some support1 report
-
Altimmune tests Pemvidutide for MASH treatment and plans FDA engagement, attracting attention from Goldman Sachs.Some support2 reports2 developments inside
-
Galectin Therapeutics develops therapies targeting MASH cirrhosis, and Uihlein converts debt to common stock.Some support2 reports
Gone quiet
No new reports in 90+ days-
Can-Fite BioPharma Ltd. is evaluating its lead drug candidate for Hepatocellular carcinoma (HCC) and is conducting a Phase IIb study for MASH.Some support3 reports
-
Gyre Therapeutics, headquartered in San Diego, is focused on developing therapies for MASH liver fibrosis.Some support1 report
-
89bio, a San Francisco-based company, is developing therapies for MASH and utilizes LinkedIn for information.Some support1 report
-
Merck advanced a vaccine trial evaluating safety and tolerability, presented at American Diabetes Association sessions.Some support1 report
-
Akero Therapeutics conducted the HARMONY clinical trial, showing that EFX reduces fibrosis in MASH patients.Some support1 report
-
FDA granted Breakthrough Therapy designation to denifanstat, a drug developed by Sagimet Biosciences for MASH treatment.Some support2 reports
-
Madrigal Pharmaceuticals' Rezdiffra, the first medication for MASH, is mentioned in the context of Trump-era tariffs and AI stock trends.Speculative1 report
-
Researchers presented pre-clinical data on combination therapies for MASH at the ADA Scientific Sessions in Chicago.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around mash this week
News at the entities that move mash most-
Altimmune, Inc. OperationalAltimmune, Inc. and Grifols are being compared as healthcare companies.Moves mash
-
Medicare StructuralMedicare reduces Social Security benefit amounts, and the Administration released new estimates for average retired worker benefits.Moves mash
-
company Mentioned togetherSilvercorp Metals Inc. is investigating potential claims on behalf of purchasers.Moves mash
-
Las Vegas Shared contextEntrepreneur relocation is driving economic growth in Las Vegas.Moves mash
Connections
The 8 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
INVENTIVA Structural
INVENTIVA focuses on developing therapies and biomarkers specifically targeting MASH.
-
Altimmune, Inc. Operational
Altimmune is actively developing and testing pemvidutide as a therapeutic approach for MASH disease.
-
Medicare Structural
Medicare provides the coverage framework for the treatment of MASH.
-
alt Operational
Company alt is conducting clinical trials targeting the MASH condition.
-
Aligos Therapeutics, Inc. Operational
Aligos Therapeutics is actively developing therapies specifically designed to treat MASH subjects.
-
company Mentioned together
Both entities are noted for developing treatments targeting metabolic dysfunction-associated steatohepatitis.
-
Wave Life Sciences Mentioned together
Wave Life Sciences is involved in clinical trials that evaluate indications, including MASH.
-
Las Vegas Shared context
The MASH experiment was hosted in Las Vegas.
History
Events by the month they beganSeptember 2026
4 events- Wave Life Sciences is developing WVE-007, an investigational GalNAc-siRNA product, for MASH indications.
- Altimmune successfully launched its global Phase 3 trial in MASH and received Breakthrough Therapy Designation from the FDA.
- Hélène Mercier develops treatments for MASH and obtains an AMP from INSEAD.
- Tangram Therapeutics is developing investigational treatments aimed at addressing the condition MASH (metabolic dysfunction-associated steatohepatitis).
August 2026
1 eventJune 2026
11 events- Galectin Therapeutics, led by CEO Joel Lewis, participated in a conference on September 2, 2025, discussing their work on developing therapies for MASH with cirrhosis.
- INVENTIVA, a company focusing on MASH therapies, held leadership conferences in New York City and Brussels.
- Altimmune tests Pemvidutide for MASH treatment and plans FDA engagement, attracting attention from Goldman Sachs.
- Can-Fite BioPharma Ltd. is evaluating its lead drug candidate for Hepatocellular carcinoma (HCC) and is conducting a Phase IIb study for MASH.
- Gyre Therapeutics, headquartered in San Diego, is focused on developing therapies for MASH liver fibrosis.
- 89bio, a San Francisco-based company, is developing therapies for MASH and utilizes LinkedIn for information.
- Merck advanced a vaccine trial evaluating safety and tolerability, presented at American Diabetes Association sessions.
- Akero Therapeutics conducted the HARMONY clinical trial, showing that EFX reduces fibrosis in MASH patients.
- FDA granted Breakthrough Therapy designation to denifanstat, a drug developed by Sagimet Biosciences for MASH treatment.
- Madrigal Pharmaceuticals' Rezdiffra, the first medication for MASH, is mentioned in the context of Trump-era tariffs and AI stock trends.
- Researchers presented pre-clinical data on combination therapies for MASH at the ADA Scientific Sessions in Chicago.